Literature DB >> 27771245

Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy.

Annemiek Dols1, Filip Bouckaert2, Pascal Sienaert3, Didi Rhebergen4, Kristof Vansteelandt5, Mara Ten Kate6, Francois-Laurent de Winter7, Hannie C Comijs4, Louise Emsell8, Mardien L Oudega4, Eric van Exel4, Sigfried Schouws4, Jasmien Obbels3, Mike Wattjes6, Frederik Barkhof6, Piet Eikelenboom9, Mathieu Vandenbulcke7, Max L Stek4.   

Abstract

OBJECTIVE: The clinical profile of late-life depression (LLD) is frequently associated with cognitive impairment, aging-related brain changes, and somatic comorbidity. This two-site naturalistic longitudinal study aimed to explore differences in clinical and brain characteristics and response to electroconvulsive therapy (ECT) in early- (EOD) versus late-onset (LOD) late-life depression (respectively onset <55 and ≥55 years).
METHODS: Between January 2011 and December 2013, 110 patients aged 55 years and older with ECT-treated unipolar depression were included in The Mood Disorders in Elderly treated with ECT study. Clinical profile and somatic health were assessed. Magnetic resonance imaging (MRI) scans were performed before the first ECT and visually rated.
RESULTS: Response rate was 78.2% and similar between the two sites but significantly higher in LOD compared with EOD (86.9 versus 67.3%). Clinical, somatic, and brain characteristics were not different between EOD and LOD. Response to ECT was associated with late age at onset and presence of psychotic symptoms and not with structural MRI characteristics. In EOD only, the odds for a higher response were associated with a shorter index episode.
CONCLUSION: The clinical profile, somatic comorbidities, and brain characteristics in LLD were similar in EOD and LOD. Nevertheless, patients with LOD showed a superior response to ECT compared with patients with EOD. Our results indicate that ECT is very effective in LLD, even in vascular burdened patients.
Copyright © 2017 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depression; early onset; electroconvulsive therapy; late life; late onset; response; structural brain

Mesh:

Year:  2016        PMID: 27771245     DOI: 10.1016/j.jagp.2016.09.005

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  8 in total

1.  Heterogenous Subtypes of Late-Life Depression and Their Cognitive Patterns: A Latent Class Analysis.

Authors:  Li-Qi Wang; Tian-Hong Zhang; Wei Dang; Sha Liu; Zi-Li Fan; Li-Hui Tu; Ming Zhang; Hua-Ning Wang; Nan Zhang; Qin-Ying Ma; Ying Zhang; Hui-Zi Li; Lu-Chun Wang; Yao-Nan Zheng; Huali Wang; Xin Yu
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

2.  Resilience predicts remission in antidepressant treatment of geriatric depression.

Authors:  Kelsey T Laird; Helen Lavretsky; Natalie St Cyr; Prabha Siddarth
Journal:  Int J Geriatr Psychiatry       Date:  2018-07-23       Impact factor: 3.485

3.  The Global ECT-MRI Research Collaboration (GEMRIC): Establishing a multi-site investigation of the neural mechanisms underlying response to electroconvulsive therapy.

Authors:  Leif Oltedal; Hauke Bartsch; Ole Johan Evjenth Sørhaug; Ute Kessler; Christopher Abbott; Annemieke Dols; Max L Stek; Lars Ersland; Louise Emsell; Philip van Eijndhoven; Miklos Argyelan; Indira Tendolkar; Pia Nordanskog; Paul Hamilton; Martin Balslev Jorgensen; Iris E Sommer; Sophie M Heringa; Bogdan Draganski; Ronny Redlich; Udo Dannlowski; Harald Kugel; Filip Bouckaert; Pascal Sienaert; Amit Anand; Randall Espinoza; Katherine L Narr; Dominic Holland; Anders M Dale; Ketil J Oedegaard
Journal:  Neuroimage Clin       Date:  2017-02-14       Impact factor: 4.881

4.  Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome.

Authors:  Elisabeth Maria van Zutphen; Didi Rhebergen; Eric van Exel; Mardien Leoniek Oudega; Filip Bouckaert; Pascal Sienaert; Matthieu Vandenbulcke; Max Stek; Annemieke Dols
Journal:  Transl Psychiatry       Date:  2019-05-24       Impact factor: 6.222

5.  Exploring resting state connectivity in patients with psychotic depression.

Authors:  Mardien L Oudega; Ysbrand D van der Werf; Annemieke Dols; Mike P Wattjes; Frederik Barkhof; Filip Bouckaert; Mathieu Vandenbulcke; François-Laurent De Winter; Pascal Sienaert; Piet Eikelenboom; Max L Stek; Odile A van den Heuvel; Louise Emsell; Didi Rhebergen; Eric van Exel
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

6.  A longitudinal study of the association between basal ganglia volumes and psychomotor symptoms in subjects with late life depression undergoing ECT.

Authors:  M G A Van Cauwenberge; F Bouckaert; K Vansteelandt; C Adamson; F L De Winter; P Sienaert; J Van den Stock; A Dols; D Rhebergen; M L Stek; L Emsell; M Vandenbulcke
Journal:  Transl Psychiatry       Date:  2021-04-01       Impact factor: 6.222

7.  The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression.

Authors:  Dore Loef; Kristof Vansteelandt; Mardien L Oudega; Philip van Eijndhoven; Angela Carlier; Eric van Exel; Didi Rhebergen; Pascal Sienaert; Mathieu Vandenbulcke; Filip Bouckaert; Annemiek Dols
Journal:  Brain Behav Immun Health       Date:  2021-11-16

8.  Neural Substrates of Psychotic Depression: Findings From the Global ECT-MRI Research Collaboration.

Authors:  Akihiro Takamiya; Annemiek Dols; Louise Emsell; Christopher Abbott; Antoine Yrondi; Carles Soriano Mas; Martin Balslev Jorgensen; Pia Nordanskog; Didi Rhebergen; Eric van Exel; Mardien L Oudega; Filip Bouckaert; Mathieu Vandenbulcke; Pascal Sienaert; Patrice Péran; Marta Cano; Narcis Cardoner; Anders Jorgensen; Olaf B Paulson; Paul Hamilton; Robin Kampe; Willem Bruin; Hauke Bartsch; Olga Therese Ousdal; Ute Kessler; Guido van Wingen; Leif Oltedal; Taishiro Kishimoto
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.